Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
RIGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.48 - $29.82
Previous CloseN/A
Volume99.93K
Average Volume (3M)250.21K
Market Cap
$365.34M
Enterprise Value$284.66M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)95.2
Beta2.35
Next Earnings
Feb 27, 2025EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.22
Shares Outstanding17,615,040
10 Day Avg. Volume282,869
30 Day Avg. Volume250,207
Standard Deviation0.28
R-Squared0.06
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.32
Price to Cash Flow (P/CF)4.20
P/FCF Ratio3.90
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.59
Enterprise Value/Ebitda21.70
Forecast
1Y Price Target
$34.00Price Target Upside64.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRigel reported strong growth across its commercial portfolio, with net sales reaching $38.9 million in 3Q24, a 44% increase compared to $27.1 million in 3Q23.
Pipeline AdvancementsRigel Pharmaceuticals has announced the enrollment of the first patient in its Phase 1 trial evaluating fostamatinib in sickle cell disease, highlighting a significant step forward in exploring the drug's potential to address unmet needs in this condition.
Strategic PartnershipsRigel announced an exclusive license and supply agreement with Kissei Pharmaceuticals for the development and commercialization of Rezlidhia in Japan, the Republic of Korea, and Taiwan.
Bears Say
Safety ConcernsRigel announced the issuance of a Dear Health Care Provider letter regarding a new safety signal for Gavreto relating to increased risk of severe infections.
---
Ownership Overview
5.45% Insiders
25.40% Mutual Funds
22.37% Other Institutional Investors
35.97% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RIGL FAQ
What was Rigel’s price range in the past 12 months?
Rigel lowest stock price was $7.48 and its highest was $29.82 in the past 12 months.
What is Rigel’s market cap?
Rigel’s market cap is $365.34M.
When is Rigel’s upcoming earnings report date?
Rigel’s upcoming earnings report date is Feb 27, 2025 which is in 6 days.
How were Rigel’s earnings last quarter?
Rigel released its earnings results on Nov 07, 2024. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of $0.058 by $0.642.
Is Rigel overvalued?
According to Wall Street analysts Rigel’s price is currently Undervalued.
Does Rigel pay dividends?
Rigel does not currently pay dividends.
What is Rigel’s EPS estimate?
Rigel’s EPS estimate is 0.45.
How many shares outstanding does Rigel have?
Rigel has 17,615,040 shares outstanding.
What happened to Rigel’s price movement after its last earnings report?
Rigel reported an EPS of $0.7 in its last earnings report, beating expectations of $0.058. Following the earnings report the stock price went up 42.94%.
Which hedge fund is a major shareholder of Rigel?
Among the largest hedge funds holding Rigel’s share is Graham Capital Management, L.P.. It holds Rigel’s shares valued at 0.
---
Rigel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$34.00 (64.89% Upside)
$34.00 (64.89% Upside)
Blogger Sentiment
Bullish
RIGL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $424.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▲ 9.0%
Last 30 Days ▲ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
76.23%
12-Months-Change
Fundamentals
Return on Equity
-26.52%
Trailing 12-Months
Asset Growth
20.89%
Trailing 12-Months
Company Description
Rigel
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
---
RIGL Company Deck
---
RIGL Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Rigel Pharmaceuticals reported strong financial performance with significant revenue growth and international expansion. The addition of GAVRETO contributed positively, although there were minor challenges in transitioning certain accounts. Overall, the company achieved positive net income, marking a successful quarter.Read More>---
RIGL Stock 12 Month Forecast
Average Price Target
$34.00
▲(64.89% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Alkermes
―
BioMarin Pharmaceutical
―
Incyte
―
Vertex Pharmaceuticals
―
Best Analysts Covering RIGL
1 Year
1 Year Success Rate
13/14 ratings generated profit
1 Year Average Return
+67.59%
reiterated a buy rating last month
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +67.59% per trade.
---